WAY 123783

Drug Profile

WAY 123783

Latest Information Update: 06 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 13 May 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 27 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
  • 18 May 2001 Preclinical development for Diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top